Eli Lilly joins Illumina's Billion Cell Atlas for AI drug discovery

Eli Lilly has joined Illumina's Billion Cell Atlas as a foundational participant, gaining access to what is described as the world's largest genome-wide genetic perturbation dataset. The Billion Cell Atlas alliance is sequencing hundreds of millions of cells to map disease mechanisms and identify new drug targets. The dataset uses CRISPR to capture how individual cells respond to genetic changes, spanning more than 200 disease-relevant cell lines and totaling over six petabytes of functional genomics data.

For Eli Lilly, the timing of this move comes as the company's stock has demonstrated strong multi-year appreciation — up 4.0% over the past week, 12.0% year to date, and 60.3% over the past year, with three- and five-year returns of 172.0% and 383.3%, respectively. The company's current pipeline narrative centers on GLP-1 obesity and diabetes drugs, a focus that has driven much of this stock performance. However, the Billion Cell Atlas partnership offers a way to broaden that narrative into higher-value specialty areas like neuroscience and cardiometabolic disease by improving target selection and understanding of disease mechanisms.

The move positions Eli Lilly alongside peers such as AstraZeneca and Merck in what could become core infrastructure for AI-powered drug discovery. This long-term capability development reflects how the company is thinking beyond its current GLP-1 franchise. Yet investors and analysts watching the stock may not yet fully appreciate how large shared genomics platforms could enhance future pipeline quality, as the market's focus remains primarily on GLP-1 volume, pricing pressure, and major late-stage assets. The alliance also carries complexity: the scale of the dataset increases R&D spending needs, which ties into existing concerns about therapeutic area concentration and the risk that expensive late-stage programs may not all succeed.